[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573768":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":49,"collaborators":52,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"UMC Utrecht","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chronic kidney disease stage 3-5",null,"Participants with an age of 18 years or older and with CKD stage 3-5 (an estimated glomerular filtration rate of 60 mL\u002Fmin\u002F1.73m\\^2 or lower for at least three months). Participants need to have an indication to start with furosemide as part of routine patient care.",[13],"Diagnostic Test: Invasive measurements",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Invasive measurements","Blood and urine samples will be collected during the study.",[9],[21],{"name":22,"affiliation":5,"role":23},"Karin GF Gerritsen, MD, PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Dian P Bolhuis, MD, MSc","CONTACT","+31-887557375","d.p.bolhuis-3@umcutrecht.nl",{"name":22,"role":27,"phone":28,"phoneExt":10,"email":31},"k.g.f.gerritsen@umcutrecht.nl",[33],{"facility":34,"status":35,"city":36,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University Medical Center Utrecht (UMCU)","RECRUITING","Utrecht","3584 CX","Netherlands","NL",{"type":41,"coordinates":42},"Point",[43,44],5.12222,52.09083,{"lat":44,"lon":43},[47,48],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":31},{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Karin G.F. Gerritsen","Associate professor, MD",[53,56],{"name":54,"class":55},"Maastricht University, MERLN Institute for Technology-Inspired Regenerative Medicine","UNKNOWN",{"name":57,"class":6},"Utrecht Institute for Pharmaceutical Sciences","100573768","study-to-examine-the-effect-of-the-diuretic-furosemide-on-the-plasma-levels-of-toxins-and-the-removal-of-toxins-from-the-blood-in-patients-with-chronic-kidney-disease-100573768",false,"NCT06750575","Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease","The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease","FUROPBUT","Inclusion Criteria:\n\n* An age of 18 years or older\n* An eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2 for at least three months (diagnosis of CKD stage 3-5)\n* An indication for the start of treatment with furosemide as part of routine patient care\n* Willingness to participate in the study and a signed informed consent\n\nExclusion Criteria:\n\n* Patients who are already on furosemide treatment\n* Patients with a liver disease with hyperbilirubinemia\n* Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis)\n* Patients with end-stage renal failure without residual diuresis\n* Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding\n* Patients who are incapacitated","ALL","18 Years",{"count":69,"type":70},34,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine.\n\nParticipants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following:\n\n* Blood pressure measurement\n* Blood sample withdrawal\n* Urine sample collection\n* 12-hour urine collection\n\nThen, one to four weeks after starting with furosemide treatment, patients will undergo the following:\n\n* Blood pressure measurement\n* Blood sample prior to furosemide intake (Tmin)\n* Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected)\n* Urine sample collection 60-120 minutes after furosemide intake\n* 12-hour urine collection\n\nThe investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.",[74,75],"Chronic Kidney Diseases","Renal Failure Chronic",[77,78,79,80,81],"Furosemide","Drug-toxin interactions","Protein-bound uremic toxins","P-cresyl sulfate","Indoxyl sulfate","2024-12-19",{"date":84,"type":85},"2024-12-27","ACTUAL",{"date":87,"type":85},"2024-06-10",{"date":89,"type":70},"2025-07-01",{"name":5,"class":6},1]